12. Congenital myasthenic syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 5 / Drugs : 7 - (DrugBank : 3) / Drug target genes : 5 - Drug target pathways : 13
Congenital myasthenic syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 12 | Congenital myasthenic syndrome | - |
| 13 | Multiple sclerosis/Neuromyelitis optica | 5.000 |
| 6 | Parkinson disease | 5.000 |
| 11 | Myasthenia gravis | 5.000 |
| 3 | Spinal muscular atrophy | 5.000 |
| 14 | Chronic inflammatory demyelinating polyneuropathy | 3.467 |
| 4 | Primary lateral sclerosis | 3.368 |
| 111 | Congenital myopathy | 1.000 |